- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Latest Articles in natco pharma
Natco Pharma Reports Multifold Rise In Consolidated Net Profit To Rs 320.4 Cr
The company had posted a consolidated net profit of Rs 75 crore in the same period last fiscal,
Read MoreNatco Pharma Signs Agreement With MPP To Sell Molnupiravir Capsules
Natco Pharma Ltd said it has signed a non-exclusive license agreement with the Medicines Patent Pool (MPP), Switzerland to manufacture and sell Molnupiravir capsules 200 mg for treatment of COVID-19.
Read MoreNatco Pharma's Marketing Partner Gets USFDA Nod For Anti-Cancer Drug
Natco Pharma said based on the ANDA filing date, the company believes that it is eligible for 180 days of sole generic marketing exclusivity for the 10 mg strength and shared 180 days of generic marketing exclusivity for the 60 mg strength of the product at the time of launch.
Read MoreNatco Pharma Initiates Molnupiravir Phase 3 Trials
Patients treated with Molnupiravir achieved response within five days of therapy, indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy
Read MoreNatco Seeks CDSCO Approval For Phase-III Trial Of Molnupiravir For COVID-19 Treatment
Natco Pharma has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of phase-III clinical trial of Molnupiravir capsules for the treatment of COVID-19 positive patients
Read MoreNatco Pharma Board Okays Acquiring 1% In Canadian Arm
Stocks of Natco Pharma were trading 0.74 per cent lower at Rs 810.85 apiece on BSE.
Read MoreNatco's Marketing Partner Gets USFDA Nod For Cancer Treatment Drug
Natco's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Read MoreNatco Pharma Q3 Net Profit Declines 39 % To Rs 63 Cr
The consolidated total income of the company stood at Rs 386 crore for the quarter under consideration. It was Rs 513 crore for the same period a year ago
Read MoreNatco Pharma Gets Registration Approval From CIB&RC For Chlorantraniliprole
CTPR is an active ingredient used in products commercialised by US-based chemicals maker FMC under brands Coragen and Ferterra.
Read MoreNatco Pharma Q2 Net Profit Up 73% To Rs 204 Cr
The company had posted a net profit of Rs 117.7 crore for the corresponding period of the previous fiscal, Natco Pharma said in a BSE filing.
Read MoreUS Patent Ruling On Teva's Copaxone A Big Win For India
US Patent and Trade Mark Office’s decision to reject the patent claims of Teva Pharmaceutical Industries on its 40-milligram dosage of multiple sclerosis drug Copaxone is undoubtedly a booster dose for the generic drug industry and the Indian drug makers in particular
Read More